Skip Navigation

Cardiovascular Research 1998 39(2):401-412; doi:10.1016/S0008-6363(98)00090-X
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hu, K.
Right arrow Articles by Ertl, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, K.
Right arrow Articles by Ertl, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin

Kai Hu, Peter Gaudron, Hans-Joachim Anders, Frank Weidemann, Oliver Turschner, Matthias Nahrendorf and Georg Ertl*

II. Medizinische Klinik, Klinikum Mannheim der Universität Heidelberg, Mannheim, Germany

* Corresponding author. Tel. +49 621 3832204; Fax: +49 621 3833821

Objective: The long-term effects and mechanisms of early started angiotensin converting enzyme (ACE) inhibition post myocardial infarction (MI) are not well understood. Chronic effects of early ACE inhibition on hemodynamics, left ventricular diastolic wall stress and remodeling were, therefore, compared to that of angiotensin AT1-receptor subtype blockade in rats with experimental myocardial infarction. The contribution of bradykinin potentiation to both ACE inhibitor and angiotensin AT1-receptor subtype blockade was assessed by cotreatment of rats with a bradykinin B2-receptor antagonist. Methods: MI was produced by coronary artery ligation in adult male Wistar rats. The ACE inhibitor, quinapril (6 mg/kg per day), or the angiotensin AT1-receptor subtype blocker, losartan (10 mg/kg per day), administered by gavage, and the bradykinin B2-receptor antagonist, Hoe-140 (500 µg/kg per day s.c.), administered either alone or in combination with quinapril or losartan, were started 30 min after MI and continued for eight weeks. Results: Quinapril and losartan reduced left ventricular end-diastolic pressure and global left ventricular diastolic wall stress only in rats with large MI. Pressure volume curves showed a rightward shift in proportion to MI size that was not prevented by quinapril or losartan treatment. Only the ACE inhibitor reduced left ventricular weight and this effect was prevented by cotreatment with the bradykinin antagonist. Baseline and peak cardiac index and stroke volume index, as determined using an electromagnetic flowmeter before and after an acute intravenous volume load, were restored by quinapril, whereas losartan had no effects. Conclusion: Treatments starting 30 min after coronary artery ligation, with either quinapril or losartan, reduced preload only in rats with large MI. Despite this unloading of the heart, structural dilatation was not prevented by this early treatment. Only quinapril improved cardiac performance and reduced left ventricular weight and this effect was abolished by cotreatment with Hoe-140, suggesting an angiotensin II blockade-independent, but bradykinin potentiation-dependent, mechanism.

KEYWORDS Myocardial infarction; Remodeling; ACE-inhibition; AT1-receptor; Bradykinin; Rats


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. E. Gonzalez, I. M. Seropian, M. L. Krieger, J. Palleiro, M. A. Lopez Verrilli, M. M. Gironacci, S. Cavallero, L. Wilensky, V. H. Tomasi, R. J. Gelpi, et al.
Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H375 - H386.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. L. Hansen, J. T. Hansen, T. Speerschneider, C. Lyngso, N. Erikstrup, E. S. Burstein, D. M. Weiner, T. Walther, N. Makita, T. Iiri, et al.
Lack of Evidence for AT1R/B2R Heterodimerization in COS-7, HEK293, and NIH3T3 Cells: HOW COMMON IS THE AT1R/B2R HETERODIMER?
J. Biol. Chem., January 16, 2009; 284(3): 1831 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y. Nakamura, M. Yoshiyama, T. Omura, K. Yoshida, Y. Izumi, K. Takeuchi, S. Kim, H. Iwao, and J. Yoshikawa
Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction
Cardiovasc Res, January 1, 2003; 57(1): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
Yuejin Yang, Yida Tang, Yingmao Ruan, Yongli Li, Yanwen Zhou, Runlin Gao, Jilin Chen, and Zaijia Chen
Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 31 - 35.
[Abstract] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
L. A.M. Zornoff, S. A.R. Paiva, B. B. Matsubara, L. S. Matsubara, and J. Spadaro
Combination Therapy with Angiotensin Converting Enzyme Inhibition and AT1 Receptor Inhibitor on Ventricular Remodeling After Myocardial Infarction in Rats
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 203 - 209.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.